kareo - the ins & outs of meaningful use stage 2

36
PAGE 1 KAREO | CONFIDENTIAL Listen. Learn. Implement. The Ins & Outs of Meaningful Use Stage 2

Upload: kareo

Post on 07-May-2015

585 views

Category:

Health & Medicine


1 download

DESCRIPTION

Watch recorded webinar: http://www.kareo.com/resources/webinars Listen. Learn. Implement. The Ins & Outs of Meaningful Use Stage 2

TRANSCRIPT

Page 1: Kareo - The Ins & Outs of Meaningful Use Stage 2

PAGE 1 KAREO | CONFIDENTIAL

Listen. Learn. Implement.The Ins & Outs of Meaningful Use

Stage 2

Page 2: Kareo - The Ins & Outs of Meaningful Use Stage 2

PAGE 2 KAREO | CONFIDENTIAL

Your Hosts Today…

Elizabeth WoodcockMBA, FACMPE, CPC

Lea ChathamContent Marketing Manager, Kareo

Page 3: Kareo - The Ins & Outs of Meaningful Use Stage 2

PAGE 3 KAREO | CONFIDENTIAL

Discover Kareo … www.kareo.com

Over 17,000 providers use Kareo to improve operations and patient care.

When your practice runs better, your patients feel it.

Electronic Health Records

Practice management

Billing Services

Page 4: Kareo - The Ins & Outs of Meaningful Use Stage 2

PAGE 4 KAREO | CONFIDENTIAL

Elizabeth Woodcock, MBA, FACMPE, CPC

Professional Speaker, Trainer, & Author

Specializing in Medical Practice Management

Author of 12 Best-Selling Practice Management Books

Fellow in the American College of Medical Practice Executives

Certified Professional Coder

MBA in Healthcare Management from The Wharton School of Business

BA from Duke University

Elizabeth W. Woodcock, MBA, FACMPE, CPCWoodcock & Associates

Speaker, Trainer, AuthorAtlanta, Georgia404.373.6195

[email protected]

Page 5: Kareo - The Ins & Outs of Meaningful Use Stage 2

PAGE 5 KAREO | CONFIDENTIAL

Background

February 2009American Recovery and Reinvestment Act

“TITLE XIII—HEALTH INFORMATION TECHNOLOGY”

HITECH Act

“Eligible professionals” will be paid for “demonstrating use of a qualified electronic health record in a meaningfulmanner.”

Logo: CMS.gov

Page 6: Kareo - The Ins & Outs of Meaningful Use Stage 2

PAGE 6 KAREO | CONFIDENTIAL

Background

Meaningful Use

Stage One

Stage Two

Stage Three

September 4, 2012 Federal Register 21050Final Rule: Medicare and Medicaid Programs; Electronic Health Record Incentive Program – Stage 2

Page 7: Kareo - The Ins & Outs of Meaningful Use Stage 2

PAGE 7 KAREO | CONFIDENTIAL

Background

Vendors received the “Final Rule” on the constitution of CEHRT systems

Certified EHR 

Technology (CEHRT)Photo: Teenspeak.org

Page 8: Kareo - The Ins & Outs of Meaningful Use Stage 2

PAGE 8 KAREO | CONFIDENTIAL

Background

In order to allow time for vendors to create and physicians to implement…

Stage Two 2014

Page 9: Kareo - The Ins & Outs of Meaningful Use Stage 2

PAGE 9 KAREO | CONFIDENTIAL

Background

1st Year

Stages of Meaningful Use2011 2012 2013 2014 2015 2016 2017

2011 1 1 1 2 2 3 32012 1 1 2 2 3 32013 1 1 2 2 32014 1 1 2 22015 1 1 22016 1 12017 1

Year One: 90 DaysSubsequent Years: 365 Days

Page 10: Kareo - The Ins & Outs of Meaningful Use Stage 2

PAGE 10 KAREO | CONFIDENTIAL

Background

1st Year

Meaningful Use Annual Incentive Payments2011 2012 2013 2014 2015 2016 [….] TOTAL

2011 MCR $18,000  $12,000  $8,000  $4,000  $2,000  $0    $0    $44,000 MCD $21,250  $8,500  $8,500  $8,500  $8,500  $8,500  $0    $63,750 

2012 MCR $18,000  $12,000  $8,000  $4,000  $2,000  $0    $44,000 MCD $21,250  $8,500  $8,500  $8,500  $8,500  $8,500  $63,750 

2013 MCR $15,000  $12,000  $8,000  $4,000  $0    $39,000 MCD $21,250  $8,500  $8,500  $8,500  $17,000  $63,750 

2014 MCR $12,000  $8,000  $4,000  $0    $24,000 MCD $21,250  $8,500  $8,500  $25,500  $63,750 

2015 MCR $0 $0    $0   $0   MCD $21,250  $8,500 $34,000 $63,750 

2016 MCR $0    $0 $0 MCD $21,250  $  42,500  $63,750 

MCR = Medicare; MCD = Medicaid. MCD participants must begin participation by 2016.

Page 11: Kareo - The Ins & Outs of Meaningful Use Stage 2

PAGE 11 KAREO | CONFIDENTIAL

Background

20143-month reporting period

First‐time Stage TwoSecond‐year Stage OneFor Medicare, must correspond with the fiscal quarter  four chances

Page 12: Kareo - The Ins & Outs of Meaningful Use Stage 2

PAGE 12 KAREO | CONFIDENTIAL

Meaningful Use: Stage One

Core Measures

15Menu

Measures

5CQMs*

6 MUMeaningful

Use

Meaningful Use: Stage Two

Core Measures

17Menu

Measures

3CQMs

9 MUMeaningful

Use

Stage Two

*One of the “core measures”; CQM: clinical quality measure

Page 13: Kareo - The Ins & Outs of Meaningful Use Stage 2

PAGE 13 KAREO | CONFIDENTIAL

•Maintain core-menu structure– 17 core objectives– 3 of 6 menu– Retain exclusions, but can’t use them to disqualify

•9 clinical quality measures (CQMs)– No longer one of the criteria– Considered part and parcel of MU

Stage Two

Page 14: Kareo - The Ins & Outs of Meaningful Use Stage 2

PAGE 14 KAREO | CONFIDENTIAL

Stage Two

Criteria Old (MU1) Threshold

New (MU2) Threshold

CPOE 30% (med) 60% (med); 30% (lab/rad)

eRx 40% 50%

Demographic info 50% 80%

Vitals 50% 80%

Smoking status 50% 80%

Clinical summaries 50% (3 days) 50% (1 day)

Patient education 10% (menu) 10% (core)CPOE: Computerized Physician Order Entry

Page 15: Kareo - The Ins & Outs of Meaningful Use Stage 2

PAGE 15 KAREO | CONFIDENTIAL

Stage Two

In addition to higher measure thresholds…

• Completely new criteria

• Stage One menu-based criteria now core

• Multi-layer criteria

Cartoon: Doug Savage

Page 16: Kareo - The Ins & Outs of Meaningful Use Stage 2

PAGE 16 KAREO | CONFIDENTIAL

Stage Two

Page 17: Kareo - The Ins & Outs of Meaningful Use Stage 2

PAGE 17 KAREO | CONFIDENTIAL

Objective: Record smoking status for patients 13+ years old

Measure: >80% of all unique patients 13+ years old seen by the EP have smoking status recorded as structured data

Stage Two: Sample MU Core Criteria

Page 18: Kareo - The Ins & Outs of Meaningful Use Stage 2

PAGE 18 KAREO | CONFIDENTIAL

Objective: Provide clinical summaries for patients for each office visit

Measure: Clinical summaries provided to patients or patient-authorized representatives for >50% of office visits

Stage Two: Sample MU Core Criteria

Page 19: Kareo - The Ins & Outs of Meaningful Use Stage 2

PAGE 19 KAREO | CONFIDENTIAL

Objective: Use clinically relevant information to identify patients who should receive reminders for preventive/follow-up care and send these patients the reminders, per patient preference

Measure: >10% of all unique patients who have had 2+ office visits with the EP within the past 24 months before the beginning of the EHR reporting period were sent a reminder, per patient preference

Stage Two: Sample MU Core Criteria

Page 20: Kareo - The Ins & Outs of Meaningful Use Stage 2

PAGE 20 KAREO | CONFIDENTIAL

Stage Two: Sample MU Core Criteria

Objective: Provide patients the ability to view online, download and transmit their health information with 4 business days of the information being available to the EP

*for both measures, only patients seen by the eligible professional (EP) during the reporting period

Measure: (1) >50% of all unique patients are provided timely online access (4 business days) to their health information; and (2) >5% of all unique patients (or authorized representative) view, download or transmit to a third party their health information*

Page 21: Kareo - The Ins & Outs of Meaningful Use Stage 2

PAGE 21 KAREO | CONFIDENTIAL

Objective: Use electronic messaging to communicate with patients on relevant health information

CEHRT: certified electronic health record technology

Measure: A secure message was sent using the electronic messaging function of CEHRT by >5% of unique patients (or their authorized representatives) seen by the EP during the EHR reporting period

Stage Two: Sample MU Core Criteria

Appendix

Page 22: Kareo - The Ins & Outs of Meaningful Use Stage 2

PAGE 22 KAREO | CONFIDENTIAL

Stage Two: Menu-based Criteria

•Capability to submit electronic syndromicsurveillance data to public health agencies

•Record electronic notes in patient records• Imaging results accessible through CEHRT•Record patient family health history• Identify and report cancer cases to a public health central cancer registry

• Identify and report specific cases to a specialized registry (other than a cancer registry)

CEHRT: Certified Electronic Health Record Technology

Page 23: Kareo - The Ins & Outs of Meaningful Use Stage 2

PAGE 23 KAREO | CONFIDENTIAL

Meaningful Use: Stage Two

Core Measures

17Menu

Measures

3CQMs

9 MUMeaningful

Use

Stage Two

*One of the “core measures”; CQM: clinical quality measure

Out of 6

Page 24: Kareo - The Ins & Outs of Meaningful Use Stage 2

PAGE 24 KAREO | CONFIDENTIAL

Clinical quality measures– 9 measures out of 64– None are “required” but some are recommended– Electronic submission as of 2014, in Year Two+– Alignment with existing quality programs▪PQRS▪Shared Savings Program (ACOs)▪NCQA Patient-Centered Medical Home Recognition

PQRS: Physician Quality Reporting System; ACO: accountable care organization; NCQA: National Committee for Quality AssuranceCMS: Centers for Medicare & Medicaid Services

Stage Two: Clinical Quality Measures

Page 25: Kareo - The Ins & Outs of Meaningful Use Stage 2

PAGE 25 KAREO | CONFIDENTIAL

Stage Two: Clinical Quality Measures

CQM domains• Patient and family engagement• Patient safety• Care coordination• Population and public health• Efficient use of healthcare resources• Clinical processes/effectiveness

9 required measures must come from at least three different domains

Page 26: Kareo - The Ins & Outs of Meaningful Use Stage 2

PAGE 26 KAREO | CONFIDENTIAL

Confirmation that penalties begin in 2015

Avoidance of penalties1. Ineligible for program2. Successful participant in 20133. At minimum, successful participant by October 1,2014

▪ Register by July 1, 2014▪ Attest by the end of September 2014

…or meet one of the criteria for exclusion

Medicare Payment Adjustments

Page 27: Kareo - The Ins & Outs of Meaningful Use Stage 2

PAGE 27 KAREO | CONFIDENTIAL

Medicare Payment Adjustments

Criteria for Exclusion▪ Infrastructure: Lack Internet availability/barriers to

obtaining IT infrastructure

▪ New eligible professional (2 years)

▪ Unforeseen circumstances (e.g., natural disasters)

▪ Particular specialty/physician▪ Limited interaction with patients

▪ Lack of control of EHR access

▪ Taxonomy codes: 30 (Diagnostic Rad); 36 (Nuclear Med); 94 (Interventional Rad*); 30 (Anesthesiology); and 22 (Pathology)

*Exclusion under review by CMS (1/2/13)

Page 28: Kareo - The Ins & Outs of Meaningful Use Stage 2

PAGE 28 KAREO | CONFIDENTIAL

•Important– Adjustments will be applied to all Medicare

reimbursement– Medicaid reimbursement will not be affected– Medicaid participants need to demonstrate

meaningful use to avoid Medicare adjustments– Must continue to demonstrate meaningful use

Medicare Payment Adjustments

Page 29: Kareo - The Ins & Outs of Meaningful Use Stage 2

PAGE 29 KAREO | CONFIDENTIAL

Medicare Payment Adjustments

Year eRx PQRS EHR Total2012 -1.0% - - -1.0%2013 -1.5% - - -1.5%2014 -2.0% - - -2.0%2015 -2.0% -1.5% -1.0% -4.5%2016 -2.0% -2.0% -4.0%2017 -2.0% -3.0% -5.0%2018 -2.0% up to -5% up to -7%2019 -2.0% up to -5% up to -7%

Page 30: Kareo - The Ins & Outs of Meaningful Use Stage 2

PAGE 30 KAREO | CONFIDENTIAL

Question & Answer Session

Page 31: Kareo - The Ins & Outs of Meaningful Use Stage 2

Listen. Learn. Implement.The Ins & Outs of

Meaningful UseStage 2

Your Questions… 

Page 32: Kareo - The Ins & Outs of Meaningful Use Stage 2

PAGE 32 KAREO | CONFIDENTIAL

Source

September 4, 2012 Federal Register 21050Final Rule: Medicare and Medicaid Programs; Electronic Health Record Incentive Program –Stage 2

http://www.gpo.gov/fdsys/pkg/FR-2012-09-04/pdf/2012-21050.pdf

Page 33: Kareo - The Ins & Outs of Meaningful Use Stage 2

PAGE 33 KAREO | CONFIDENTIAL

Appendix: Remaining MU Core Criteria

• Incorporate clinical lab-test results into CEHRT as structured data

• Generate lists of patients by specific conditions to use for quality improvement, reduction of disparities, research or outreach

• Use clinically relevant information from CEHRT to identify patient-specific education resources and provide those resources to the patient

• The EP who receives a patient from another setting of care or provider of care or believes an encounter is relevant should perform medication reconciliation

Page 34: Kareo - The Ins & Outs of Meaningful Use Stage 2

PAGE 34 KAREO | CONFIDENTIAL

Appendix : Remaining MU Core Criteria

• The EP who transitions their patient to another setting of care or provider of care or refers their patient to another provider of care should provide summary care record for each transition of care or referral

• Capability to submit electronic data to immunization registries or immunization information systems except where prohibited, and in accordance with application law and practice

• Use CPOE for medication, laboratory and radiology orders directly entered by any licensed healthcare professional who can enter orders into the medical record per state, local and professional guidelines

• Generate and transmit permissible prescriptions electronically (eRx)

Page 35: Kareo - The Ins & Outs of Meaningful Use Stage 2

PAGE 35 KAREO | CONFIDENTIAL

Appendix : Remaining MU Core Criteria

• Record the following demographics: preferred language, sex, race, ethnicity, date of birth

• Record and chart changes in vital signs• Use clinical decision support to improve performance on

high priority health conditions• Protect electronic health information created or maintained

by the CEHRT through the implementation of appropriate technical capabilities

Page 36: Kareo - The Ins & Outs of Meaningful Use Stage 2

PAGE 36 KAREO | CONFIDENTIAL

Elizabeth W. Woodcock, MBA, FACMPE, CPCWoodcock & AssociatesSpeaker, Trainer, Author

Atlanta, Georgia404.373.6195

[email protected]

Your Speaker